Welcome to Xi’an Good Doctor Medical Science and Technology Co., Ltd.website ！
Internet Drug Information Service Qualification Certificate: (Shaanxi)-Non-Operating -2023-0143
Reposted: A chronic illness flares up—new opportunities in diagnosis and treatment emerge! Hyperthermic Intraperitoneal Chemotherapy offers a fresh path to hope for patients with advanced peritoneal tumors.
Malignant thoracic and abdominal tumors accompanied by peritoneal implantation, refractory ascites, and postoperative recurrence have long posed significant clinical challenges.
2026-06-25
Malignant thoracic and abdominal tumors accompanied by peritoneal implantation, refractory ascites, and postoperative recurrence have long posed formidable clinical challenges. Conventional systemic radiotherapy and chemotherapy struggle to eradicate microscopic tumor foci within the abdominal cavity, while systemic adverse effects are pronounced, leading to progressive disease deterioration in many patients with advanced cancer who have undergone multiple lines of therapy. The First People’s Hospital of Jingzhou and the First Affiliated Hospital of Yangtze University’s Department of Gastrointestinal Oncology I routinely perform hyperthermic intraperitoneal chemotherapy (HIPEC), opening a new therapeutic pathway for patients with recurrent, refractory thoracoabdominal malignancies. Ms. Wu, a 63-year-old patient with malignant peritoneal mesothelioma—whose name has been changed—is a direct beneficiary of this minimally invasive, precision‑guided technique.
Over the four years of her illness, Auntie Wu was plagued by persistent abdominal distension and massive ascites. She underwent multiple rounds of chemotherapy and targeted therapy, yet her condition continued to relapse, her tolerance markedly declined, and the unrelenting pain left her physically and emotionally exhausted. In April 2026, her abdominal distension worsened dramatically; imaging revealed copious fluid accumulation in the abdominopelvic cavity, thickening of the peritoneum, and progressive tumor growth, making it difficult to maintain normal eating or sleep.
Upon taking the case, Director Hu Yan of the Oncology Department at the First Municipal Hospital promptly convened a multidisciplinary team for a comprehensive assessment. Taking into account the patient’s prolonged disease course, repeated recurrences, and overall frailty, she tailored an individualized hyperthermic intraperitoneal chemotherapy regimen and initiated treatment without delay. To date, Auntie Wu has completed the full course of therapy; her postoperative recovery has been stable, with marked relief from persistent abdominal distension, effective control of peritoneal effusion, and a significant improvement in her quality of life.
Hyperthermic intraperitoneal chemotherapy leverages the physiological characteristic of tumor cells—namely, their intolerance to high temperatures—by maintaining a constant 43°C and continuously circulating a chemotherapeutic solution within the peritoneal cavity. Through the combined effects of thermal inactivation, localized high‑concentration chemotherapy, and mechanical flushing, this approach eliminates free cancer cells and occult micrometastases in the abdominal cavity, thereby reducing the risk of tumor recurrence at its source.
Compared with conventional systemic antitumor therapies, this technique offers distinct advantages: the perfusate can achieve complete coverage of the entire thoracic and abdominal cavities, eliminating treatment blind spots; chemotherapeutic agents are concentrated at the tumor site, with only minimal systemic exposure, resulting in milder toxicities and better tolerability even in frail patients with advanced cancer; moreover, it can rapidly alleviate malignant symptoms such as ascites, abdominal pain, and bloating, thereby improving patients’ quality of life while also controlling tumor progression over the long term and extending survival.
This diagnostic and therapeutic technique has a broad range of applications. In addition to malignant peritoneal mesothelioma, it can be used for thoracoabdominal malignancies such as gastric cancer, colorectal cancer, ovarian cancer, liver cancer, and pancreatic cancer—particularly when these cancers are associated with peritoneal implantation metastases, refractory malignant pleural or peritoneal effusions, a high risk of postoperative recurrence, or progression following multiple lines of therapy. It is suitable both for postoperative prevention of tumor recurrence and for palliative symptom‑relief treatment in patients with advanced disease.
The successful implementation of this technology has addressed critical gaps in the diagnosis and treatment of advanced-stage tumors, particularly in eradicating microscopic disease foci and managing malignant ascites. The First Municipal Hospital stated that it will continue to deepen its expertise in precision oncology, leveraging cutting-edge medical technologies and a highly skilled multidisciplinary team to fortify the life‑saving care of cancer patients across the province and offer them greater hope for survival.
Key words:
Related News
· China Good Doctor ·
· Good friends of human beings ·
Address: Floor 1-2, Left Building No. 1, Huoju Road, East zone of Xi’an High- tech Development District, Xi’an, China
Copyright Xi'an Good Doctor Medical Technology Co., Ltd.
Internet Drug Information Service Qualification Certificate (Shaanxi)-Non-Operating -2023-0143